Neil Riordan PhD

Professional Site

Home Intellectual Property

Intellectual Property

Patents / Publication

Patents / Publication # Year of Publication / Issued Title Citations
2013/0156,726 2013 ENDOMETRIAL STEM CELLS AND METHODS OF MAKING AND USING SAME 0
2012/0276,215 2012 Therapeutic Conditioned Media 0
2012/0269,774 2012 ALLOGENEIC STEM CELL TRANSPLANTS IN NON-CONDITIONED RECIPIENTS 0
2012/0195,969 2012 TREATMENT OF ACNE BY CONDITIONED MEDIA 0
2011/0135,759 2011 STEM CELL/ENDOTHELIAL PROGENITOR CELL MOBILIZATION BY NUTRACEUTICAL FORMULATIONS 0
2011/0117,650 2011 Vessel and method for isolating cells from tissue portions 0
2011/0104,100 2011 COMPOSITIONS AND METHODS OF STEM CELL THERAPY FOR AUTISM 0
2010/0261,152 2010 METHOD FOR EXPANSION OF STEM CELLS 0
7,749,495 2010 Method for inducing an anti-tumor and anti-cachexia immune response in mammals 0
2009/0291,061 2009 STEM CELL THERAPY FOR BLOOD VESSEL DEGENERATION 1
2009/0053,182 2009 ENDOMETRIAL STEM CELLS AND METHODS OF MAKING AND USING SAME 1
2008/0254,005 2008 Stem Cell Therapy for the Treatment of Autism and Other Disorders 1
2008/0219,958 2008 METHOD FOR INDUCING AN ANTI-TUMOR AND ANTI-CACHEXIA IMMUNE RESPONSE IN MAMMALS 0
2006/0222,641 2006 Method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism 0
2006/0182,724 2006 Method for expansion of stem cells 10
6,827,940 2004 Immune-stimulating bacterial cell wall extracts 3
2004/0228,925 2004 Method for inducing an anti-tumor and anti-cachexia immune response in mammals 0
2004/0223,962 2004 Method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism 6
6,599,538 2003 High molecular weight extracts of Convolvulus arvensis (field bindweed) and Polygonum convolvulus (wild buckwheat) 0
6,596,322 2003 High molecular weight extracts of Convolvulus arvensis (field bindweed) and Polygonum convolvulus (wild buckwheat) 1
6,448,287 2002 Treatment of cancer using lipoic acid in combination with ascorbic acid 3
6,436,411 2002 Cancer treatment method 0
2002/0037,917 2002 Treatment of cancer using lipoic acid in combination with ascorbic acid 0
2002/0022,036 2002 Method for inducing an anti-tumor and anti-cachexia immune response in mammals 0
6,284,786 2001 Treatment of cancer using lipoic acid in combination with ascorbic acid 5
6,083,510 2000 High molecular weight extracts of Convolvulus arvensis field (field bindweed) 2
5,866,142 1999 Skin treatment system 6
5,639,787 1997 Therapeutic method for the treatment of cancer 10
5,480,613 1996 Apparatus kit for detecting Dientamoeba fragilis 3
5,334,509 1994 Method for detecting intestinal pathogen dientamoeba fragilis 4

http://www.patentbuddy.com/Inventor/Riordan-Neil-H/7913322#More

 

Issued Patents

The invention relates to inducing an immune response toward tumor associated antigens and in particular to the administration of high molecular weight isolates of autologous urine either alone, with adjuvants, or with antigen presenting cells. The antigen presenting cells have been cocultured with isolates of autologous urine. The invention can also be used to treat cachexia in cancer or AIDS patients.

A method of obtaining a pharmacologically active extract of the cell walls of Gram-positive bacteria is disclosed. The method involves the treatment of the bacteria with acid such that the immune-stimulating properties are enhanced. The extracts have immune stimulating and anti-tumor activities with no toxicity at effective doses. The final products are stable, water-soluble powders.

A bindweed and buckwheat extract is used to inhibit the growth of tumor cells, inhibit the growth of blood vessels, and enhance immune function. The bindweed and buckwheat extract requires minimal purification and produces a low toxicity anti-tumor and immuno-stimulating extract.

A bindweed and buckwheat extract is used to inhibit the growth of tumor cells, inhibit the growth of blood vessels, and enhance immune function. The bindweed and buckwheat extract requires minimal purification and produces a low toxicity anti-tumor and immunostimulating extract.

Lipoic acid and/or its water soluble salt is used to treat cancer, alone or in combination with ascorbic acid (vitamin C). Alone or in combination, it was shown to be effective on in vitro tumors and mouse tumors. The agents can be administered safely, and have been used effectively in case studies.

Treatment of tumors, including their metastases, is described. Retrieved cytokines and other molecules from the growth medium of human monocytes stimulated ex vivo with gamma globulin, or other immune stimulators are employed for cancer therapy.

Lipoic acid and/or its water soluble salt is used to treat cancer, alone or in combination with ascorbic acid (vitamin C). Alone or in combination, it was shown to be effective on in vitro tumors and mouse tumors. The agents can be administered safely, and have been used effectively in case studies.

A purified bindweed extract is used to inhibit the growth of tumor cells, inhibit the growth of blood vessels, and enhance immune function. The bindweed extract is prepared by removing toxic low molecular weight components of Convolvulus arvensis.

A skin treatment system comprises preparations for the topical application to the skin of histidine acting as a divalent cation chelator and exfoliant, pyridoxine and pantothenic acid and N-acetyl-D-glucosamine for increasing production of hyaluronic acid, superoxide dismutase and cysteine and vitamin E for decreasing the oxidative degradation of the hyaluronic acid, and pyroll carboxylic acid, or chemical salts thereof, and hyaluronic acid, or chemical salts thereof for providing increased hydration of the skin.

A method of treating cancer in a patient by raising and maintaining the concentration of ascorbic acid, or ascorbate, in the patient’s plasma to at least the level expected to be toxic to an in vitro culture of cells of the type of cancer being treated, the required plasma ascorbate levels being achieved and maintained using long term intravenous infusions of large amounts of ascorbate, with or without ascorbate cytotoxicity effectiveness enhancing or tumor site delivery and absorption enhancing agents.

A method and apparatus for producing detectable intestinal parasites. The method includes obtaining an intestinal mucosa sample (e.g. feces) having intestinal parasites, such as Dientamoeba fragilis; and contacting the obtained intestinal mucosa sample with an acridine base compound (e.g. acridine orange and/or acridine yellow, etc.) such that the intestinal parasites become differentially stained and detectable by a human eye when viewed through a fluorescence microscope. The apparatus includes a kit or the like which includes at least one vessel or vial. Preferably, two vials are contained within the kit with one vial having an isotonic salt solution including a salt, sodium chloride, potassium phosphate, etc., and the other vial containing an acridine biological staining compound.

A method and apparatus for producing detectable intestinal parasites. The method includes obtaining an intestinal mucosa sample (e.g. feces) having intestinal parasites, such as Dienamoeba fragilis; and contacting the obtained intestinal mucosa sample with an acridine base compound (e.g. acridine orange and/or acridine yellow, etc.) such that the intestinal parasites become differentially stained and detectable by a human eye when viewed through a fluorescence microscope. The apparatus includes a kit or the like which includes at least one vessel or vial. Preferably, two vials are contained within the kit with one vial having an isotonic salt solution including a salt, such as sodium chloride, potassium phosphate, etc., and the other vial containing an acridine biological staining compound.

Pending Patents

Compositions of matter, uses, and formulations of food supplements/nutrients capable of eliciting mobilization of various stem/progenitor cells, including hematopoietic stem cells and endothelial progenitor cells are disclosed. In one embodiment a formulation contains a mixture of ellagic acid, vitamin D3, beta 1,3 glucan and a ferment of the bacterium, Lactobacillus fermentum, with an extract of green tea, extract of goji berries, and extract of the root of astragalus added prior to fermentation. Said formulation, originally developed as an antioxidant/immune stimulator was found to have the unexpected property of eliciting stem/progenitor cell mobilization.

A vessel is adapted to be used in a procedure for isolating and collecting cells from a tissue portion using a centrifuge by providing a sealable chamber separated into two sections by a mesh screen, the chamber having a conical bottom inner surface, with a port at the apex in the lowest point in the chamber and ports at the top of the chamber, the method including placing the tissue portion in the chamber above the screen, washing the tissue, repeatedly as needed, by introducing a washing solution through a top port and draining the wash solution from the chamber through the bottom port, introducing an enzyme solution through a top port, allowing the enzyme solution to partially digest the tissue, centrifuging the vessel, and draining the isolated cells through the bottom port.

Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of substantially ameliorating or reversing the progression of autism through the administration of autologous and/or allogeneic stem cells, alone or in combination with mobilization agents. The use of stem cells and cells naturally possessing or endowed with angiogenic and anti-inflammatory activity are disclosed for autism either alone or in combination with various therapeutic interventions.

A method of increasing the growth of stem cells by mixing the stem cells with a growth medium that has been conditioned by an incubation with placental tissue. The method increases the expansion of the stem cell population.

The present invention provides mesenchymal stem cells and mesenchymal-like cells useful for treatment of muscular dystrophies including Duchenne Muscular Dystrophy (DMD), as well as, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss dystrophies. Also provided are protocols for administration of cells for treatment of the above dystrophies and adjuvant protocols. Futhermore, the invention teaches methods of manipulating mesenchymal and mesenchymal-like cells in vitro and in vivo for augmentation of therapeutic effects. Particularly, use of endometrial regenerative cells, alone or in combination with mesenchymal stem cells is provided for treatment of DMD and Becker muscular dystrophy.

The present disclosure provides means of treating degenerated blood vessels through administration of stem cells or activators of stem cells. In one particular embodiment vessel reactivity is increased through administration of stem cells or stem cell activating compounds. Other embodiments include “reconditioning” of vessels prone to aneurysms, repairing aneurysms of vessels, or acceleration of endothelialization after stent placement. Provided within the invention are methods of rejuvenating properties of said vessels associated with physiological health, examples of which include appropriate production of anti-coagulating/clotting factors, control of angiogenesis, and appropriate revascularization of injured tissue.

The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium.

Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.

Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin.

Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of inducing angiogenesis and immune modulation either in sequence or parallel in order to substantially ameliorate or reverse the progression of autism. The use of stem cells, and cells naturally possessing or endowed with angiogenic and anti-inflammatory activity are disclosed for autism either alone or in combination with various therapeutic interventions.

Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of inducing angiogenesis and immune modulation either in sequence or parallel in order to substantially ameliorate or reverse the progression of autism. The use of stem cells, and cells naturally possessing or endowed with angiogenic and anti-inflammatory activity are disclosed for autism either alone or in combination with various therapeutic interventions.

The present invention relates to a composition and method for preventing or reducing edema, deep vein thrombosis (DVT), and/or pulmonary embolism by administering a combination of a fibrinolytic agent and an antioxidant. The composition is particularly useful for treating individuals prior to or during long term flights or other situations involving extended immobility.

A method of increasing the growth of stem cells by mixing the stem cells with a growth medium that has been conditioned by an incubation with placental tissue. The method increases the expansion of the stem cell population.

Neil Riordan 9-29-2011
www.neilriordan.net